Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 combined with Ribociclib in HER2-positive Advanced Breast Cancer
NCT06481956Phase 2Enrolling by invitation
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer. Primary endpoint: Objective Response Rate up to 54 months. Started Oct 2023; status: enrolling by invitation.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06481956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481956.